(S)-1-[4-(3-trichloromethyl-benzyloxy)-benzyl]-pyrrolidine-2-carboxylic acid amide | 849909-86-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-1-[4-(3-trichloromethyl-benzyloxy)-benzyl]-pyrrolidine-2-carboxylic acid amide
• 英文别名: (2S)-1-[[4-[[3-(trichloromethyl)phenyl]methoxy]phenyl]methyl]pyrrolidine-2-carboxamide
• CAS: 849909-86-0
• 化学式: C₂₀H₂₁Cl₃N₂O₂
• 分子量: 427.758
• InChiKey: BWSBZOUKSOAJHL-SFHVURJKSA-N

物化性质

• 沸点：
  573.5±50.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1524265A1

  公开（公告）日：2005-04-20

  This invention is related to novel prolinamide derivatives and analogues of general formula I    wherein Qis C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or saturated or unsaturated 5 to 7 membered ring optionally containing one or more heteroatoms chosen independently from nitrogen, oxygen or sulphur, the rings being optionally substituted by one or more halogen atoms, trifluoromethyl, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy; Xis an oxygen, sulphur or a NR5 group; R, R1are independently hydrogen, C1-C6 alkyl, halogen, trifluoromethyl, hydroxy or C1-C6 alkoxy; R2,is hydrogen or hydroxyl; R3, R4, R5are independently hydrogen or straight or branched C1-C3 alkyl; nis an integer from 1 to 3    and a pharmaceutically acceptable salt or prodrug thereof, that are active as sodium and/or calcium channel modulators and/or as selective MAO-B inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.

  本发明涉及新型脯氨酰胺衍生物和一般式I的类似物 其中，Q为C3-C8烷基，或C1-C8烷基，其被苯氧基或饱和或不饱和的5至7元环替代，该元环可以选择一个或多个杂原子，独立地从氮、氧或硫中选择，所述环可以选择一个或多个卤素原子，三氟甲基，C1-C6烷基，羟基，C1-C6烷氧基替代；X为氧、硫或NR5基团；R、R1独立地为氢、C1-C6烷基、卤素、三氟甲基、羟基或C1-C6烷氧基；R2为氢或羟基；R3、R4、R5独立地为氢或直链或支链状的C1-C3烷基；n为1至3的整数；以及其药学上可接受的盐或前药。这些化合物作为钠和/或钙通道调节剂和/或选择性MAO-B抑制剂具有活性，因此在预防、缓解和治愈广泛的病理学，包括但不限于神经、精神、心血管、炎症、眼科、泌尿科、代谢和胃肠疾病中有用，其中上述机制已被描述为发挥病理作用。
• [EN] PROLINAMIDE DERIVATIVES AS SODIUM AND/OR CALCIUM CHANNEL BLOCKERS OR SELECTIVE MAO-B INHIBITORS<br/>[FR] DERIVES DE PROLINAMIDE SERVANT DE BLOQUEURS DE CANAUX CALCIQUES ET/OU SODIQUES, OU D'INHIBITEURS SELECTIFS DE LA MAO-B
  申请人：NEWRON PHARM SPA

  公开号：WO2005040108A1

  公开（公告）日：2005-05-06

  This invention is related to novel prolinamide derivatives and analogues of general formula (I) wherein Q is C3-C8 alkyl, or C1-C8 alkyl substituted by phenoxy or saturated or unsaturated 5 to 7 membered ring optionally containing one or more heteroatoms chosen independently from nitrogen, oxygen or sulphur, the rings being optionally substituted by one or more halogen atoms, trifluoromethyl, C1-C6 alkyl, hydroxyl, C1-C6 alkoxy; X is an oxygen, sulphur or a NR5 group; R, R1 are independently hydrogen, C1-C6 alkyl, halogen, trifluoromethyl, hydroxy or C1-C6 alkoxy; R2 is hydrogen or hydroxyl; R3 R4 R5 are independently hydrogen or straight or branched C1-C3 alkyl; n is an integer from 1 to 3 and a pharmaceutically acceptable salt or prodrug thereof, that areactive as sodium and/or calcium channel modulators and/or as selective MAOB inhibitors and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.